https://www.yiliao.com/index.php?action=history&feed=atom&title=%E9%A3%9F%E7%AE%A1%E8%85%BA%E7%99%8C
食管腺癌 - 版本历史
2026-04-18T06:34:05Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=%E9%A3%9F%E7%AE%A1%E8%85%BA%E7%99%8C&diff=314505&oldid=prev
223.160.136.36：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2026-01-15T05:53:27Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>[[食管腺癌]]</strong>（<strong>[[Esophageal Adenocarcinoma]]</strong>）是起源于[[食管]]黏膜[[腺上皮]]的恶性肿瘤，主要发生于食管下1/3段及<strong>[[胃食管结合部]]</strong>（[[GEJ]]）。与[[食管鳞癌]]不同，其发病与<strong>[[胃食管反流病]]</strong>（[[GERD]]）及由此诱发的<strong>[[巴雷特食管]]</strong>（[[Barrett's Esophagus]]）密切相关。[[食管腺癌]]具有高度的[[分子异质性]]，常伴有<strong>[[ERBB2]]</strong>（[[HER2]]）扩增、<strong>[[VEGFA]]</strong>过表达及<strong>[[CLDN18.2]]</strong>异常表达。随着[[精准医疗]]的发展，治疗模式已由传统化疗演变为包括[[免疫检查点抑制剂]]（如[[PD-1单抗]]）及新型[[抗体偶联药物]]（[[ADC]]）在内的多模态综合治疗。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 320px; float: right; margin: 0 0 25px 25px; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #ffffff 0%, #e0f2fe 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">[[食管腺癌]]</div><br />
<div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px;">[[Esophageal Adenocarcinoma]] · 点击展开详情</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 20px; text-align: center; background-color: #f8fafc;"><br />
<div style="padding: 10px; border: 1px solid #e2e8f0; border-radius: 8px; background: #fff; display: inline-block;"><br />
<div style="width: 140px; height: 90px; background-color: #f1f5f9; display: flex; align-items: center; justify-content: center; color: #94a3b8; font-size: 0.8em; padding: 10px; text-align: center;">[[EAC]]病理组织浸润示意图</div><br />
</div><br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">[[ICD-10]]代码：C15.5</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;"><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 40%;">核心驱动基因</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">[[TP53]]•[[ERBB2]]•[[FGFR2]]</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">关键靶点</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #b91c1c;">[[PD-L1]]•[[CLDN18.2]]•[[HER2]]</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">主要诱因</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">[[巴雷特食管]]•[[肥胖]]</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">血清标志物</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;">[[CEA]]•[[CA19-9]]</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569;">转移方式</th><br />
<td style="padding: 12px; color: #0f172a;">[[淋巴转移]]•[[血行转移]]</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">发病机制：炎症驱动的克隆演变</h2><br />
<br />
<p style="margin: 15px 0; text-align: justify;"><br />
[[食管腺癌]]的发生遵循典型的多阶段演进模式，即“[[胃食管反流]]-高级别[[化生]]-不典型增生-癌变”：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>[[巴雷特食管]]恶变：</strong>由于胃酸及胆汁长期反流，食管下段的[[复层鳞状上皮]]被[[单层柱状上皮]]取代。在此过程中，<strong>[[TP53]]</strong>基因的早期缺失是细胞进入不稳定状态的关键。</li><br />
<li style="margin-bottom: 12px;"><strong>[[基因组不稳定性]]：</strong>[[EAC]]具有极高的[[拷贝数变异]]。[[ERBB2]]（约15-20%）及[[FGFR2]]、[[MET]]等受体[[酪氨酸激酶]]基因的扩增驱动了细胞的异常[[增殖]]。</li><br />
<li style="margin-bottom: 12px;"><strong>[[微环境]]免疫逃逸：</strong>肿瘤细胞通过过表达[[PD-L1]]抑制[[T细胞]]活性，且常伴随<strong>[[CLDN18.2]]</strong>蛋白的异位表达，使其成为[[靶向治疗]]的潜在位点。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">临床分型与精准治疗矩阵</h2><br />
<br />
<div style="overflow-x: auto; margin: 25px auto; width: 95%;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.9em; text-align: left;"><br />
<tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;"><br />
<th style="padding: 10px; border: 1px solid #cbd5e1; color: #0f172a; width: 25%;">分子/病理亚型</th><br />
<th style="padding: 10px; border: 1px solid #cbd5e1; color: #475569;">关键特征</th><br />
<th style="padding: 10px; border: 1px solid #cbd5e1; color: #1e40af;">推荐治疗策略</th><br />
</tr><br />
<tr><br />
<td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[HER2]]阳性型</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">[[IHC]]3+或[[FISH]]阳性</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">[[曲妥珠单抗]]联合[[化疗]]；二线使用[[德曲妥珠单抗]]([[T-DXd]])。</td><br />
</tr><br />
<tr><br />
<td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[PD-L1]]高表达型</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">[[CPS]]评分≥5/10</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">[[纳武利尤单抗]]或[[帕博利珠单抗]]联合[[双铂化疗]]。</td><br />
</tr><br />
<tr><br />
<td style="padding: 8px; border: 1px solid #cbd5e1; font-weight: 600;">[[CLDN18.2]]阳性型</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">中高强度膜染色</td><br />
<td style="padding: 8px; border: 1px solid #cbd5e1;">[[佐妥昔单抗]]([[Zolbetuximab]])或国产[[CLDN18.2-ADC]]药物。</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">诊疗策略：多学科协作与全程管理</h2><br />
<p style="margin: 15px 0; text-align: justify;"><br />
[[食管腺癌]]的现代管理强调基于[[TNM分期]]与[[分子检测]]的综合干预：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>[[围手术期]]干预：</strong>对于可切除的局限期患者，推荐采用[[FLOT方案]]（[[氟尿嘧啶]]+[[奥沙利铂]]+[[多西他赛]]）或[[CROSS研究]]定义的[[新辅助放化疗]]。</li><br />
<li style="margin-bottom: 12px;"><strong>[[免疫辅助]]治疗：</strong>基于[[CheckMate-577]]研究，接受过新辅助放化疗且术后仍有[[病理残留]]的患者，应进行[[纳武利尤单抗]]维持治疗。</li><br />
<li style="margin-bottom: 12px;"><strong>晚期一线[[精准选药]]：</strong>必须进行[[HER2]]、[[PD-L1]]、[[MSI]]及[[CLDN18.2]]检测。对于[[MSI-H]]患者，[[免疫单药]]即可获得持久缓解。</li><br />
<li style="margin-bottom: 12px;"><strong>[[ADC]]药物突围：</strong>针对[[HER2]]中低表达或耐药患者，[[德曲妥珠单抗]]（[[DS-8201]]）展现了突破性的[[客观缓解率]]，正改写晚期治疗格局。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">关键相关概念</h2><br />
<div style="background-color: #f8fafc; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin: 20px 0;"><br />
<ul style="margin: 0; padding-left: 20px; color: #334155;"><br />
<li style="margin-bottom: 8px;"><strong>[[巴雷特食管]]：</strong>[[食管腺癌]]最主要的癌前病变，需定期行[[胃镜]]及[[活检]]随访。</li><br />
<li style="margin-bottom: 8px;"><strong>[[GEJ]]分型：</strong>[[Siewert分型]]（I/II/III型）决定了[[手术切除]]范围及重建方式。</li><br />
<li style="margin-bottom: 8px;"><strong>[[CPS]]评分：</strong>用于评估[[PD-L1]]表达强度的指标，决定了[[免疫治疗]]的获益概率。</li><br />
<li style="margin-bottom: 8px;"><strong>[[FLOT方案]]：</strong>目前[[欧洲]]及[[中国]]指南推荐的[[腺癌]]标准围手术期化疗方案。</li><br />
</ul><br />
</div><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2.2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>Kelly RJ, et al. (2021).</strong> <em>Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.</em> <strong>[[The New England Journal of Medicine]]</strong>.[Academic Review]<br><br />
<span style="color: #475569;">[权威点评]：CheckMate-577研究定义了术后辅助免疫治疗的标准，使复发风险显著降低。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>Shitara K, et al. (2023).</strong> <em>Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma.</em> <strong>[[The Lancet]]</strong>.<br><br />
<span style="color: #475569;">[临床价值]：SPOTLIGHT研究证实了CLDN18.2靶点在腺癌精准化治疗中的核心地位。</span><br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;"><br />
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;"><br />
[[食管腺癌]] 诊疗生态 · 知识图谱<br />
</div><br />
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;"><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">关联靶点</td><br />
<td style="padding: 10px 15px; color: #334155;">[[ERBB2]]•[[PD-L1]]•[[CLDN18.2]]•[[FGFR2]]•[[VEGFA]]•[[MSI]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">核心药物</td><br />
<td style="padding: 10px 15px; color: #334155;">[[纳武利尤单抗]]•[[德曲妥珠单抗]]•[[佐妥昔单抗]]•[[贝伐珠单抗]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">战略实体</td><br />
<td style="padding: 10px 15px; color: #334155;">[[NCCN]]•[[CSCO]]•[[BMS]]•[[Merck]]•[[Daiichi Sankyo]]•[[Astellas]]</td><br />
</tr><br />
<tr><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">研究前沿</td><br />
<td style="padding: 10px 15px; color: #334155;">[[针对HER2耐药的联合ADC方案]]•[[游离DNA监测微小残留病灶]]•[[双抗针对CLDN18.2的开发]]</td><br />
</tr><br />
</table><br />
</div><br />
<br />
</div></div>
223.160.136.36